Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na+/H+ Exchanger Isoform 3

We present herein the design, synthesis, and optimization of gut-restricted inhibitors of Na+/H+ exchanger isoform 3 (NHE3). NHE3 is predominantly expressed in the kidney and gastrointestinal tract where it acts as the major absorptive sodium transporter. We desired minimally systemic agents that wo...

Full description

Saved in:
Bibliographic Details
Published in:ACS medicinal chemistry letters 2022-07, Vol.13 (7), p.1043-1051
Main Authors: Jacobs, Jeffrey W., Leadbetter, Michael R., Bell, Noah, Koo-McCoy, Samantha, Carreras, Christopher W., He, Limin, Kohler, Jill, Kozuka, Kenji, LabonteĢ, Eric D., Navre, Marc, Spencer, Andrew G., Charmot, Dominique
Format: Article
Language:English
Subjects:
Letter
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We present herein the design, synthesis, and optimization of gut-restricted inhibitors of Na+/H+ exchanger isoform 3 (NHE3). NHE3 is predominantly expressed in the kidney and gastrointestinal tract where it acts as the major absorptive sodium transporter. We desired minimally systemic agents that would block sodium absorption in the gastrointestinal tract but avoid exposure in the kidney. Starting with a relatively low-potency highly bioavailable hit compound (1), potent and minimally absorbed NHE3 inhibitors were designed, culminating with the discovery of tenapanor (28). Tenapanor has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of irritable bowel syndrome with constipation in adults.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.2c00037